The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|11|3|154-155

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.11, Iss.3, 2018-12, pp. : 154-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

By  

Current Radiopharmaceuticals, Vol. 11, Iss. 3, 2018-12 ,pp. : 200-208

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies

By  

Current Radiopharmaceuticals, Vol. 11, Iss. 3, 2018-12 ,pp. : 192-199

Bentham Science Publishers

Access to resources Recommend Favorite

Actinium-225 in Targeted Alpha-Particle Therapeutic Applications

By  

Current Radiopharmaceuticals, Vol. 4, Iss. 4, 2011-10 ,pp. : 306-320

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Alpha Therapy with 213Bi

By  

Current Radiopharmaceuticals, Vol. 4, Iss. 4, 2011-10 ,pp. : 295-305

Bentham Science Publishers

Access to resources Recommend Favorite

Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy

By  

Current Radiopharmaceuticals, Vol. 1, Iss. 3, 2008-09 ,pp. : 203-208

Bentham Science Publishers

Access to resources Recommend Favorite